Cognition Therapeutics (CGTX) said Wednesday that a phase 2 study of CT1812 to treat patients with Lewy body dementia met its primary endpoint of safety and tolerability.
The drug produced "strong therapeutic responses across behavioral, functional, cognitive and movement measures" in patients who received the treatment for six months, compared to placebo.
The results showed a 82% slowing in neuropsychiatric inventory decline and a 91% reduction in attention fluctuations, while reducing anxiety, hallucinations and delusions, Cognition said.
The company said it expects to review the results with the Food and Drug Administration in an end-of-phase 2 meeting and to advance CT1812 into late-stage trials.
Cognition Therapeutics shares were 135% higher in recent premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。